---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-005212"
form_type: "8-K"
ticker: "ORMP"
cik: "0001176309"
company_name: "ORAMED PHARMACEUTICALS INC."
filed_at: "2025-01-22T23:59:59+00:00"
generated_at: "2026-05-27T18:31:45.356668+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Oramed extends Scilex note maturity to Dec 2025; receives 3.25M Scilex shares as consideration

## Summary
- Remaining principal on Tranche A Note is $7.675M; maturity extended from March 21, 2025 to December 31, 2025.
- SCLX JV transferred 3,250,000 shares of Scilex common stock to Oramed as consideration for the extension.
- Note covenants amended: cash sweep definition updated, and Scilex may not increase officer/director compensation while note outstanding.
- Oramed may waive certain prepayments and instead direct prepayment to Tranche B Note holders.
- Extension was a condition for payment deferrals under separate Tranche B Note amendments.

## SEC filing metadata
- accession: 0001213900-25-005212
- form_type: 8-K
- ticker: ORMP
- cik: 0001176309
- company_name: ORAMED PHARMACEUTICALS INC.
- filed_at: 2025-01-22T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1176309/000121390025005212/0001213900-25-005212-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1176309/000121390025005212/ea0228309-8k_oramed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-005212
- JSON: https://secwatch.observer/filing/0001213900-25-005212.json
- Plain text: https://secwatch.observer/filing/0001213900-25-005212.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.